These companies are working on treatments for cancers that have had almost no effective options for decades. If key Phase 3 trials succeed, the ripple effect across the entire sector could be enormous.
High-profile endorsements and growing institutional interest are shining a spotlight on this space right now. When professional investors and public figures start talking about a sector, it tends to move fast.
With major trial results on the horizon and regulatory momentum building, this thematic group is at an early but potentially pivotal inflection point. Getting in before the results land could make all the difference.
This basket's total market capitalisation is $26.59B and it is heavily anchored by large-cap constituents. The largest constituent represents the majority of capitalisation, so the basket's behaviour is likely to reflect large-cap stability rather than small-cap volatility.
RVMD: $19.11B
ERAS: $5.29B
CRDF: $108.02M
Former Senator Ben Sasse's spotlight on Revolution Medicines' Phase 3 trial for daraxonrasib — a daily pill targeting pancreatic cancer — has drawn fresh attention to the precision oncology space. These stocks are centred on a powerful idea: that some of the most aggressive, historically untreatable cancers, driven by complex genetic mutations known as RAS, may finally be within reach of targeted treatment. A clinical breakthrough here could shift the entire oncology sector.
This is a high-risk, high-reward thematic group. The companies included are mostly clinical-stage, meaning they are still running trials and have not yet brought products to market at scale. That means greater potential upside if trials succeed, but also real risk if they don't. This basket is best suited for investors who understand the speculative nature of early-stage biotech and are comfortable with volatility in exchange for exposure to potentially transformative milestones.
Every stock in this group was handpicked by professional analysts for its direct connection to RAS-mutation-targeted therapies or precision oncology diagnostics. From small molecule inhibitors and RNA-interference treatments to radiopharmaceuticals and live-cell encapsulation, each company is pursuing a unique angle on the same unmet medical need. These are not random picks — they represent a carefully considered cross-section of the most relevant players in this emerging field.
Former Senator Ben Sasse recently spotlighted Revolution Medicines' upcoming Phase 3 trial results for a new pancreatic cancer pill. This high-profile endorsement brings broader market attention to biotech companies developing innovative therapies for historically untreatable, RAS-dependent solid tumors.
이 바스켓의 전체 스토리를 확인하세요. 리스크와 잠재력을 다룬 상세 기사를 읽어보세요.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
4월 12 게시
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+2
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
이 자산들에 투자했다면:
12개월 후 예상 가치:
+297.08%
애널리스트들은 이 그룹의 자산이 향후 1년간 평균 297.08% 성장할 것으로 예상합니다.
이 그룹의 자산 12개 중 11개가 전문 애널리스트로부터 매수 의견을 받았습니다.
